BioRestorative Therapies (BRTX) has released an update to notify the public and investors about an entry into a material definitive agreement.
BioRestorative Therapies, Inc. has secured approximately $8.1 million in gross proceeds by restructuring its financial instruments with certain warrant holders. The company reduced the exercise price of existing warrants and issued new ones to facilitate immediate cash exercise and future capital potential. The funds will support clinical trials for its lead cell therapy candidate, BRTX-100, among other corporate purposes. This strategic financial move, compliant with Nasdaq regulations, aims to strengthen the company’s financial position and accelerate its development programs.
For further insights into BRTX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
